… for treatment. A preclinical study found that in lung cancer, IB6 … . A phase 3 trial has recently begun recruiting … Sigvie-003 trial. The rationale for the trial design was … trial specifically with sigvotatug vedotin and Keytruda as a first-line treatment …

… week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks … . • A series of FDA approvals were … the treatment of adults with EGFR-mutated non-small cell lung cancer. The …

Published December 19, 2025 at 10:33 AM EST Listen • 12:12 ChristianaCare Gene Editing Institute Digitally modified image of tumor cells with CRISPR/Cas9 affected cells in brown. The breakthrough reverses chemotherapy resistance, and the hope is this …

… trial (NCT04510129) supported the utility of the OncoPrism-non–small cell lung cancer … press release from the developer, Cofactor Genomics.1 … which [patients with] lung cancer will benefit from immunotherapy … first-line single-agent treatment or in combination …

… treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer … healthcare providers, dramatically reducing treatment time and the burden … the new formulation. The FDA decision was supported by results … to-treat form of lung cancer.

… the connection between diet and lung cancer. Scientists labelled glycogen, a … predictor" of tumour development and mortality in lung cancer sufferers, stated Ramon … of medications currently exist to regulate glycogen levels, all developed through …

… the connection between diet and lung cancer. Researchers labelled glycogen, a molecule … this illness, which sees patients develop normally for around 10 years … of treatment possibilities. Prof Gentry observed that three different types of medication …

… of global clinical trial designs and interpretability of trial results. These … multi-regional clinical development programs. A recent draft FDA guidance document20 suggests … advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383 …

… .” Trial enrollees will be able to continue treatment, … asset for drug developers relatively recently. AstraZeneca … trial testing I-DXd enrolled over 500 participants with small cell lung cancer … small cell lung cancer. The FDA granted breakthrough therapy …

… Food and Drug Administration (FDA) approval for Rybrevant Faspro … )-mutated non-small cell lung cancer (NSCLC). The approval covers … patients have previously faced limited treatment options. “Now, patients … access to this transformative treatment, as well as …